Stocks and Investing Stocks and Investing
Wed, November 8, 2017
Tue, November 7, 2017
Mon, November 6, 2017

Vamil Divan Maintained (TEVA) at Sell with Decreased Target to $8 on, Nov 6th, 2017


Published on 2024-10-26 00:39:33 - WOPRAI, Vamil Divan
  Print publication without navigation


Vamil Divan of Credit Suisse, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Sell with Decreased Target from $14 to $8 on, Nov 6th, 2017.

Vamil has made no other calls on TEVA in the last 4 months.



There are 9 other peers that have a rating on TEVA. Out of the 9 peers that are also analyzing TEVA, 6 agree with Vamil's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Gregg Gilbert of "Deutsche Bank" Downgraded from Strong Buy to Hold on, Friday, November 3rd, 2017
  • Douglas Tsao of "Barclays" Maintained at Hold with Decreased Target to $19 on, Friday, October 20th, 2017
  • Liav Abraham of "Citigroup" Downgraded from Strong Buy to Hold on, Wednesday, August 16th, 2017
  • Tyler Van Buren of "Cowen & Co." Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Aaron Gal of "Bernstein" Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Derek Archila of "Oppenheimer" Downgraded from Buy to Hold on, Thursday, August 3rd, 2017


These are the ratings of the 3 analyists that currently disagree with Vamil


  • David Risinger of "Morgan Stanley" Maintained at Sell with Decreased Target to $7 on, Friday, November 3rd, 2017
  • Tim Chiang of "BTIG" Upgraded from Hold to Strong Buy and Held Target at $24 on, Monday, September 11th, 2017
  • Randall Stanicky of "RBC Capital" Downgraded from Buy to Sell on, Friday, August 4th, 2017
Contributing Sources